Catalog Home Page

Abacavir hypersensitivity

Nolan, D., Almeida, C. and Phillips, E.J. (2007) Abacavir hypersensitivity. In: Pichler, W., (ed.) Drug Hypersensitivity. S. Karger AG, Basel, Switzerland, pp. 116-125.

Google Books Preview: http://books.google.com.au/books/about/Drug_Hypers...
*Open access. Some pages may not be available

Abstract

Abacavir is a commonly prescribed HIV drug belonging to the nucleoside reverse transcriptase inhibitor (NRTI) class. The major treatment-limiting side effect associated with its use is an early onset multi-system drug hypersensitivity reaction typically including some combination of rash, fever and gastrointestinal symptoms, occurring within 6 weeks of initiating treatment in approximately 5-8% of abacavir recipients. Susceptibility to this drug hypersensitivity syndrome is strongly predicted by the presence of a specific human leukocyte antigen (HLA) allele - HLA-B*5701-which represents the dominant risk factor for abacavir hypersensitivity among Caucasian and Hispanic populations. The frequency distribution of this genetic marker in different populations is likely to provide a rational basis for racially defined differences in susceptibility, while the critical role of HLA-B*5701 in directing CD8+ T-Cell-dependent, HLA-restricted immune responses provides a key role for this genetic variant in the pathogenesis of abacavir-specific immune responses. In this chapter, we review the implications of this genetic association for clinical practice as well as current knowledge of its immunological basis.

Publication Type: Book Chapter
Murdoch Affiliation: Centre for Clinical Immunology and Biomedical Statistics
Publisher: S. Karger AG
Copyright: 2007 S. Karger
URI: http://researchrepository.murdoch.edu.au/id/eprint/16130
Item Control Page Item Control Page